316 related articles for article (PubMed ID: 18562509)
1. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
Jung P; Beyerle A; Ziemann U
Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
[TBL] [Abstract][Full Text] [Related]
2. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
3. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
4. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
6. Prediction of long-term disability in multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486
[TBL] [Abstract][Full Text] [Related]
7. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
8. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P
Clin Neurophysiol; 2012 Feb; 123(2):406-10. PubMed ID: 21778106
[TBL] [Abstract][Full Text] [Related]
9. Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis.
O'Connor P; Marchetti P; Lee L; Perera M
Ann Neurol; 1998 Sep; 44(3):404-7. PubMed ID: 9749611
[TBL] [Abstract][Full Text] [Related]
10. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
11. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients.
Watanabe A; Matsushita T; Doi H; Matsuoka T; Shigeto H; Isobe N; Kawano Y; Tobimatsu S; Kira J
J Neurol Sci; 2009 Jun; 281(1-2):34-40. PubMed ID: 19339021
[TBL] [Abstract][Full Text] [Related]
12. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
Ozakbas S; Cagiran I; Ormeci B; Idiman E
J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
[TBL] [Abstract][Full Text] [Related]
13. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
Pelayo R; Montalban X; Minoves T; Moncho D; Rio J; Nos C; Tur C; Castillo J; Horga A; Comabella M; Perkal H; Rovira A; Tintoré M
Mult Scler; 2010 Jan; 16(1):55-61. PubMed ID: 19995838
[TBL] [Abstract][Full Text] [Related]
14. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis.
Meuth SG; Bittner S; Seiler C; Göbel K; Wiendl H
Mult Scler; 2011 Feb; 17(2):198-203. PubMed ID: 21135021
[TBL] [Abstract][Full Text] [Related]
16. Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients.
London F; El Sankari S; van Pesch V
Clin Neurophysiol; 2017 Apr; 128(4):561-569. PubMed ID: 28231474
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
18. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
19. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
20. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
